Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

480 Study: Phase 2b Open-label, Randomized Study in Treatment Naive Subjects With HCV G1 to Compare the Efficacy, Safety, and Tolerability of the 480 µg Dose of Locteron Plus Ribavirin Given Bi-Weekly to PEG-Intron Plus Ribavirin Given Weekly.

Next Previous
Trial Profile

480 Study: Phase 2b Open-label, Randomized Study in Treatment Naive Subjects With HCV G1 to Compare the Efficacy, Safety, and Tolerability of the 480 µg Dose of Locteron Plus Ribavirin Given Bi-Weekly to PEG-Intron Plus Ribavirin Given Weekly.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon alpha-2b (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms EMPOWER
  • Sponsors Biolex

Most Recent Events

  • 01 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 20 Dec 2010 Tolerability results from EMPOWER have been presented as a late-breaker at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD).
  • 02 Nov 2010 Results reported at AASLD, according to a OctoPlus media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top